← SynDRA
NRX195183
SynDRA canonical compound SYN0004007 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | RARA |
|---|
| Mechanism of action | retinoid receptor agonist |
|---|
All known targets
Mechanisms of action (all sources)
- RARA AGONIST
- Retinoic acid receptor alpha agonist
- retinoid receptor agonist
Cross-references
Synonyms
- Irx-5183
- AGN-195183
- IRX5183
- NRX-195183
- VTP-195183
- VTP-5183
- IRX-5183
- NRX-5183
- IRX-5183 (oral, autoimmune disease), Io Therapeutics
- RARa (oral, cancer/autoimmune disease), Io Therapeutics
- RARa agonist (topical, skin/eye diseases), Io Therapeutics
- Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics
- Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics
- IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics
- IRX-5183 (topical, skin/eye diseases), Io Therapeutics
- AGN195183
- NRX 195183
- RC87L028HU
- RefChem:148873
- RARa Agonist IRX5183
- RARalpha Agonist IRX5183
- UNII-RC87L028HU
- orb1707704
- SCHEMBL5531052
- GLXC-10599
- SPA27307
- BDBM50120065
- MFCD18633237
- AKOS027323480
- CS-3203
- AGN 195183?
- DA-70642
- HY-16684
- MS-27848
- NS00068774
- F85047
- T14144
- BRD-K32533226-001-01-3
Look up NRX195183 in the interactive SynDRA portal →